Private equity major Warburg Pincus has acquired Integrace, a Mumbai-based pharmaceutical company specialising in orthopedic and gynecology therapies, according to an announcement.
Integrace has a portfolio of more than 20 brands across healthcare segments and works with over 45,000 healthcare professionals through its marketing network.
As part of the transaction, True North and Temasek have fully exited Integrace, where they jointly held a 99.74% stake.
DealStreetAsia had first reported about the transaction in January this year.
“This acquisition reflects our conviction in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharmaceuticals business in India,” Himanshu Nema, Managing Director, Warburg Pincus, said in media statement.
The deal comes amid continued investor interest in India’s pharmaceutical sector, which has seen steady demand growth, with segments such as women’s health and orthopedics attracting attention from healthcare investors.
“India’s pharmaceutical market is large and attractive with predictable growth over the long-term, particularly in women’s health and orthopedic therapies,” said Rehan Khan, Chief Executive Officer, Integrace.
The acquisition marks Warburg Pincus’ continued focus on India’s healthcare sector, where the firm has invested across pharmaceuticals, medical technology, and healthcare services over the past three decades.
Its other healthcare portfolio companies include Metropolis, Laurus Labs, MedPlus, Meril Life Sciences, and Appasamy Associates.
